

Oklahoma Health Care Authority

Drug Utilization Review Board

(DUR Board)

Meeting – September 11, 2024 @ 4:00pm

at the

Oklahoma Health Care Authority (OHCA)

4345 N. Lincoln Blvd.

Oklahoma City, Oklahoma 73105

NOTE: *The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.*

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

A. Roll Call – Dr. Wilcox

DUR Board Members:

Mr. Kenneth Foster –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Bret Haymore –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person
Dr. Edna Patatanian –	participating in person
Dr. Vineetha Thomas –	participating in person
Dr. Beth Walton –	participating in person
Dr. Cindy West –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:

https://oklahoma.zoom.us/webinar/register/WN_94lCoSe9Ty2msgsLMqg2Ww

After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:

Dial: +1-602-753-0140 or +1-669-219-2599

Webinar ID: 958 2294 2095

Passcode: 65079339

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. July 10, 2024 DUR Board Meeting Minutes
- B. July 10, 2024 DUR Board Recommendations Memorandum
- C. August 14, 2024 DUR Board Recommendations Memorandum

Items to be presented by Dr. Wilson, Dr. O'Halloran, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/Direct Oral Anticoagulant (DOAC) Health Care System Utilization Following Removal of Prior Authorization (PA) Requirement – See Appendix B

- A. Pharmacy Help Desk Activity for August 2024
- B. Medication Coverage Activity for August 2024
- C. DOAC Health Care System Utilization Following Removal of PA Requirement

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Filsuvez® (Birch Triterpenes Topical Gel) and Update the Approval Criteria for the Epidermolysis Bullosa (EB) Medications – See Appendix C

- A. Market News and Updates
- B. Filsuvez® (Birch Triterpenes Topical Gel) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Kisunla™ (Donanemab-azbt) and Update the Approval Criteria for the Alzheimer's Disease Medications – See Appendix D

- A. Market News and Updates
- B. Kisunla™ (Donanemab-azbt) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Metts, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Defencath® (Taurolidine/Heparin) – See Appendix E

- A. Market News and Updates
- B. Defencath® (Taurolidine/Heparin) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Wegovy® (Semaglutide) – See Appendix F

- A. Market News and Updates
- B. Wegovy® (Semaglutide) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Sinko, Dr. Muchmore, Chairman:

9. Action Item – Vote to Prior Authorize Avzivi® (Bevacizumab-tnjn) and Fruzaqla® (Fruquintinib) and Update the Approval Criteria for the Colorectal Cancer (CRC) Medications – See Appendix G

- A. Market News and Updates
- B. Fruzaqla® (Fruquintinib) Product Summary
- C. Cost Comparison: Bevacizumab Products
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

10. Action Item – Vote to Prior Authorize Accrufer® (Ferric Maltol) and Update the Approval Criteria for the Iron Products – See Appendix H

- A. Market News and Updates
- B. Accrufer® (Ferric Maltol) Product Summary
- C. Cost Comparison: Intravenous (IV) Iron Products
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Metts, Dr. Muchmore, Chairman:

11. Action Item – Vote to Prior Authorize Doryx® MPC [Doxycycline Delayed-Release (DR) Tablet], Exblifep® (Cefepime/Enmetazobactam), Meropenem 2g Vial, Pivya™ (Pivmecillinam), Nitrofurantoin 50mg/mL Suspension, Tetracycline 250mg and 500mg Tablet, and Zevtera® (Ceftobiprole

Medocaril Sodium) and Update the Approval Criteria for the Various Systemic Antibiotics – See Appendix I

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

12. Action Item – Vote to Prior Authorize Penicillamine 250mg Tablet and Trientine 500mg Capsule and Update the Approval Criteria for the Wilson's Disease Medications – See Appendix J

- A. Market News and Updates
- B. Cost Comparisons
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Metts, Dr. Muchmore, Chairman:

13. Action Item – Vote to Prior Authorize Eohilia™ (Budesonide Oral Suspension) and Update the Approval Criteria for the Corticosteroid Special Formulations – See Appendix K

- A. Market News and Updates
- B. Eohilia™ (Budesonide Oral Suspension) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

14. Action Item – Vote to Prior Authorize Tramadol 25mg Tablet and Update the Approval Criteria for the Opioid Analgesics and Medication-Assisted Treatment (MAT) Medications – See Appendix L

- A. Cost Comparison: Tramadol
- B. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

15. Action Item – Vote to Update the Approval Criteria for the Topical Corticosteroids – See Appendix M

- A. College of Pharmacy Recommendations

Items to be presented by Dr. Metts, Dr. Muchmore, Chairman:

16. Action Item – Annual Review of Allergen Immunotherapies – See Appendix N

- A. Current Prior Authorization Criteria
- B. Utilization of Allergen Immunotherapies
- C. Prior Authorization of Allergen Immunotherapies
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Allergen Immunotherapies

Items to be presented by Dr. Sinko, Dr. Muchmore, Chairman:

17. Annual Review of Breast Cancer Medications and 30-Day Notice to Prior Authorize Hercessi™ (Trastuzumab-strf) and Truqap™ (Capivasertib) – See Appendix O

- A. Current Prior Authorization Criteria
- B. Utilization of Breast Cancer Medications
- C. Prior Authorization of Breast Cancer Medications
- D. Market News and Updates
- E. Truqap™ (Capivasertib) Product Summary
- F. Cost Comparison: Trastuzumab Products
- G. College of Pharmacy Recommendations
- H. Utilization Details of Breast Cancer Medications

Items to be presented by Dr. Metts, Dr. Muchmore, Chairman:

18. Annual Review of Amyloidosis Medications and 30-Day Notice to Prior Authorize Wainua™ (Eplontersen) – See Appendix P

- A. Current Prior Authorization Criteria
- B. Utilization of Amyloidosis Medications
- C. Prior Authorization of Amyloidosis Medications
- D. Market News and Updates
- E. Wainua™ (Eplontersen) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Amyloidosis Medications

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

19. Annual Review of Cystic Fibrosis (CF) Medications – See Appendix Q

- A. Current Prior Authorization Criteria
- B. Utilization of CF Medications
- C. Prior Authorization of CF Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of CF Medications

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

20. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix R

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

21. Future Business* (Upcoming Product and Class Reviews)

- A. Anemia Medications
- B. Hepatitis C Medications
- C. Synagis® (Palivizumab)
- D. Targeted Immunomodulator Agents

*Future product and class reviews subject to change.

22.Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.